Medicine and Dentistry
Hematopoietic Stem Cell Transplantation
82%
Transplantation
81%
Arsenic Trioxide
52%
Overall Survival
52%
Granulocyte Colony Stimulating Factor
50%
Acute Promyelocytic Leukemia
35%
Hematologic Malignancy
35%
Stem Cell Transplant
35%
Hematology
35%
Peripheral Blood Stem Cell
35%
Meta-Analysis
35%
Cytarabine
34%
Autologous Stem Cell Transplantation
33%
Disease
29%
Health Care
29%
Platelet
28%
Health Care Cost
27%
Leukocyte
26%
Event Free Survival
24%
Cisplatin
24%
Dexamethasone
24%
Allogeneic Stem Cell Transplantation
23%
Acute Leukemia
23%
Methotrexate
22%
Gemcitabine
21%
Thrombocyte Transfusion
20%
Vein Occlusion
20%
Disease Free Survival
20%
Filgrastim
20%
Clinical Trial
19%
Engraftment
19%
Allogeneic Hematopoietic Stem Cell Transplantation
19%
Tretinoin
19%
Aggressive Lymphoma
17%
Low Molecular Weight Heparin
17%
Autologous Bone Marrow Transplantation
17%
Stiff Person Syndrome
17%
Hepatic Veno-Occlusive Disease
17%
Cytomegalovirus
17%
Bendamustine
17%
Ibrutinib
17%
Bone Marrow Necrosis
17%
Intravascular Lymphoma
17%
Chronic Myelogenous Leukemia
17%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
17%
Testes
17%
Progenitor Cell
17%
Thymocyte Antibody
17%
Autotransplantation
17%
Tyrosine-Kinase Inhibitor
17%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Dexamethasone
58%
Overall Survival
55%
Cytarabine
44%
Cisplatin
41%
Graft Versus Host Reaction
38%
Gemcitabine
38%
Promyelocytic Leukemia
35%
Arsenite
35%
Lenalidomide
35%
Hematologic Malignancy
35%
Diffuse Large B Cell Lymphoma
26%
Disease
25%
Retinoic Acid
23%
Acute Leukemia
22%
Rituximab
22%
Acute Graft Versus Host Disease
22%
Multiple Myeloma
21%
Disease Free Survival
21%
Randomized Controlled Trial
20%
Fludarabine
19%
Anthracycline
19%
Remission
19%
Event Free Survival
19%
Low Molecular Weight Heparin
17%
Tacrolimus
17%
Accessory Spleen
17%
Fabry Disease
17%
Hypertensive Factor
17%
Lentivirus
17%
Prednisone
17%
Progression Free Survival
17%
Vein Occlusion
17%
Liver Vein Obstruction
17%
Acute Lymphoblastic Leukemia
17%
Mycophenolic Acid
17%
Ibrutinib
17%
Bendamustine
17%
Sorafenib
17%
Plerixafor
17%
Mouse
17%
Thymocyte Antibody
17%
Idiopathic Thrombocytopenic Purpura
17%
Romidepsin
17%
Chronic Lymphatic Leukemia
17%
High Dose Chemotherapy
17%
Melphalan
17%
Methotrexate
17%
Continuous Erythropoiesis Receptor Activator
17%
Metastatic Breast Cancer
17%
Keyphrases
Hematopoietic Stem Cell Transplantation
47%
Marrow Transplantation
42%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
42%
Older Patients
35%
Newly Diagnosed
35%
Aggressive Lymphoma
35%
Filgrastim
35%
Salvage Chemotherapy
35%
Catheter-related Thrombosis
35%
Allografting
35%
Confidence Interval
30%
Overall Survival
26%
Hematological Malignancies
26%
Bone Marrow
25%
Treatment Outcome
23%
Graft-versus-host Disease (GvHD)
20%
Venous Disease
20%
Mobilized Peripheral Blood
19%
Myeloablative
18%
Outcome Prediction
17%
Localization Studies
17%
Arsenic Trioxide
17%
Acute Promyelocytic Leukemia
17%
Pathologic
17%
Extramedullary Plasmacytoma
17%
Stiff Person Syndrome
17%
Lentivirus
17%
Clinical Trials
17%
Fabry Disease
17%
Prospective Phase II Study
17%
Plasma Mitochondrial DNA
17%
Hepatic Veno-occlusive Disease
17%
Group Randomized
17%
Previously Untreated
17%
Patient Self-assessment
17%
Cytomegalovirus Prophylaxis
17%
Bleeding Symptoms
17%
Cytomegalovirus Treatment
17%
Bendamustine-rituximab
17%
Lenalidomide
17%
Ibrutinib
17%
Red Cell Exchange
17%
Marrow
17%
Bowel Involvement
17%
Canadian Consensus
17%
Patient-level Data
17%
Intravascular Large B-cell Lymphoma (IVLBCL)
17%
Pandora's Box
17%
Low Molecular Weight Heparin
17%
Transformed Indolent Lymphoma
17%